Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 7 | Mind Blowing Facts

Moderna Says Dual Variant COVID-19 Booster With Beta is Better Effective Against Omicron Than Current Jab

Moderna Inc (NASDAQ:MRNA) said a COVID-19 booster designed to target the Beta variant and the original coronavirus generated a better immune response against several virus variants, including Omicron. Moderna said the results were a good sign for the company's plans for future shots targeting two COVID-19 variants. The company said the bivalent…

Benzinga

AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt

Key takeaways: Vaccine maker AIM has filed for an IPO in Hong Kong, following unsuccessful previous bids in Hong Kong and on Shenzhen’s ChiNext board The company has three Covid vaccines under development, including an mRNA vaccine expected to hit the market in the fourth quarter By Fai Pui

Benzinga

What Are Whales Doing With Moderna

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Britain Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Britain's medicines regulator approved the use of Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine in children between six and 11 years. The Medicines and Healthcare products Regulatory Agency (MHRA) said the approval was granted after Moderna's vaccine, known as Spikevax, met the required safety, quality, and effectiveness standards. Read Next: Why Did Moderna Recall Thousands Of COVID-19…

Benzinga

Why Did Moderna Recall Thousands Of COVID-19 Vaccine Doses In Europe?

Moderna Inc (NASDAQ:MRNA) recalled 764,900 doses of its COVID-19 vaccine made by its Spanish contract manufacturer Rovi after a foreign body contaminated a vial. No safety issues have been identified, Moderna said, about the lots distributed in Norway, Poland, Portugal, Spain, and Sweden in January. Japanese authorities last year suspended the use of…

Benzinga

What Are Whales Doing With Moderna

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

See Why COVAX, African Union Refuse To Buy More Moderna's COVID-19 Vaccine

COVAX, the global project to share COVID-19 vaccines, and the African Union have declined options to buy additional doses of Moderna Inc (NASDAQ:MRNA) COVID-19 vaccine despite the low immunization rate as developing nations struggle to allocate supplies. The African Union and Covax decided not to obtain more of the vaccine as developing nations struggle…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Moderna Shares Are Trading Lower

Moderna Inc (NASDAQ: MRNA) shares are trading lower Tuesday following reports indicating that both the African Union and COVAX Consortium have declined to purchase the company's COVID-19 vaccine doses.

Benzinga

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

Benzinga

CDC Says Heart Inflammation Risk Higher After COVID-19 Infection Than mRNA Vaccines: CNBC

According to a study published by the Centers for Disease Control and Prevention, myocarditis, pericarditis, and multisystem inflammatory syndrome w

Benzinga

What Are Whales Doing With Moderna

Benzinga

FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People

The FDA has approved a second round of the Moderna Inc (NASDAQ:

Benzinga

Check Out What Whales Are Doing With MRNA

Benzinga

What 10 Analyst Ratings Have To Say About Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Vaccine Stocks to Buy Following the Surge in COVID-19 Cases in China

China is battling with its worst COVID-19 outbreak since 2020. Surging cases of a new omicron variant worldwide are raising concerns that another COVID-19 wave is coming, which could drive demand for future vaccine orders. This bodes well for popular vaccine stocks Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX), and…

Benzinga

This Is What Whales Are Betting On Moderna

Benzinga

Moderna's COVID-19 Vaccine Shows Neutralizing Antibody Response In Kids Under 6

Moderna Inc (NASDAQ:MRNA) has announced interim data from the Phase 2/3 KidCOVE study of its COVID-19 vaccine (mRNA-1273) in children six months to under six years. The interim analysis showed that two 25 μg doses of mRNA-1273 in participants 6 months to under six years met the primary endpoint with robust neutralizing antibody…

Benzinga

Moderna Bolsters Its Pipeline With Two New mRNA-Based Vaccine Programs

Moderna Inc (NASDAQ:MRNA) expands its mRNA pipeline with two new development programs ahead of Annual Vaccines Day, building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four endemic human coronaviruses (HCoV). First, Moderna is launching a respiratory combination…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market

After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock.

StockNews.com

5 Cheap Value Stocks to Add to Your Portfolio

Despite the latest federal interest rate hikes, undervalued stocks with impressive financials are expected to deliver solid returns in the coming months. So, we think it could be wise to scoop up quality stocks Moderna (MRNA), Bayer (BAYRY), Henkel (HENKY), AGCO (AGCO), and Penske Automotive (PAG), which are currently trading…

Benzinga

Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters

Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,

Benzinga

Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose

Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a

Benzinga

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Benzinga

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

Benzinga

Here's Why Moderna Shares Are Rising

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 7.0% at $158.42. The company announced today it has reached an agreement with Japan to supply an additional 70 million doses of its COVID-19 booster vaccine.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.